Table 4.
Some of the ongoing CAR-T and CAR-NK trials.
| Name/Target | Combination | Patients’ Status |
Trial Number | Phase | Recruiting Status |
|---|---|---|---|---|---|
| Anti-BCMA/GPRC5D | RRMM | NCT05509530 | Phase II | Recruiting | |
| APRIL CAR-T cells | BCMA/TACI Positive RRMM |
NCT04657861 | Early Phase I | Recruiting | |
|
Dual Specificity
CD38 and BCMA |
RRMM | NCT03767751 | Phase I | Unknown | |
| Anti-BCMA | Fludarabine Cyclophosphamide |
MM | NCT03322735 | Phase I | Unknown |
| SLAMF7 CAR-T | MM | NCT04499339 | Phase I/IIa | Recruiting | |
|
CXCR4 modified
anti-BCMA CAR T-cells |
MM | NCT04727008 | Early Phase I | Not yet recruiting | |
| CD19-CD22 CAR-T-cells | RRMM | NCT04714827 | Phase I/II | Recruiting | |
| BCMA/CD19 Dual-Target CAR-T | RRMM | NCT04182581 | Early Phase I | Unknown | |
| CD 70 CAR T | CD70 Positive RRMM |
NCT04662294 | Early Phase I | Recruiting | |
| Anti-CD38 CAR-T | RRMM | NCT03464916 | Phase I | Completed | |
| Bispecific CAR Targeting CS1 and BCMA | RRMM | NCT03464916 | Phase I | Completed | |
| Anti-BCMA | clarithromycin, lenalidomide, dexamethasone |
NDMM | NCT04287660 | Phase III | Recruiting |
| Anti-BCMA CAR-NK | RRMM | NCT03940833 | Phase I/II | Unknown | |
| Anti-BCMA CAR-NK | Fludarabine Cytoxan |
RRMM | NCT05008536 | Early Phase I | Recruiting |
| Anti-BCMA CAR-NK | Cyclophosphamide Fludarabine Daratumumab | MM | NCT05182073 | Phase I | Recruiting |
NDMM: newly diagnosed multiple myeloma; RRMM: relapsed/refractory multiple myeloma.